Gofen & Glossberg’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $8.85M | Buy |
24,176
+372
| +2% | +$132K | 0.23% | 101 |
|
|
2022
Q3 | $7.7M | Buy |
23,804
+3,511
| +17% | +$1.11M | 0.22% | 104 |
|
|
2022
Q2 | $6.58M | Sell |
20,293
-577
| -3% | -$173K | 0.17% | 116 |
|
|
2022
Q1 | $5.98M | Sell |
20,870
-551
| -3% | -$142K | 0.14% | 127 |
|
|
2021
Q4 | $5.92M | Sell |
21,421
-591
| -3% | -$150K | 0.13% | 134 |
|
|
2021
Q3 | $5.09M | Sell |
22,012
-506
| -2% | -$125K | 0.12% | 141 |
|
|
2021
Q2 | $5.17M | Buy |
22,518
+97
| +0.4% | +$19.5K | 0.12% | 139 |
|
|
2021
Q1 | $4.19M | Sell |
22,421
-534
| -2% | -$104K | 0.11% | 143 |
|
|
2020
Q4 | $3.88M | Sell |
22,955
-103
| -0.4% | -$15.4K | 0.11% | 139 |
|
|
2020
Q3 | $3.41M | Sell |
23,058
-275
| -1% | -$42.6K | 0.11% | 138 |
|
|
2020
Q2 | $3.83M | Sell |
23,333
-220
| -0.9% | -$33.8K | 0.13% | 128 |
|
|
2020
Q1 | $3.27M | Sell |
23,553
-189
| -0.8% | -$26K | 0.13% | 127 |
|
|
2019
Q4 | $3.12M | Buy |
23,742
+831
| +4% | +$96.3K | 0.1% | 133 |
|
|
2019
Q3 | $2.56M | Buy |
22,911
+77
| +0.3% | +$8.57K | 0.09% | 144 |
|
|
2019
Q2 | $2.53M | Sell |
22,834
-47
| -0.2% | -$5.54K | 0.09% | 147 |
|
|
2019
Q1 | $2.97M | Sell |
22,881
-1,367
| -6% | -$166K | 0.11% | 135 |
|
|
2018
Q4 | $2.81M | Sell |
24,248
-98
| -0.4% | -$10.9K | 0.11% | 133 |
|
|
2018
Q3 | $2.61M | Buy |
24,346
+1,664
| +7% | +$166K | 0.09% | 153 |
|
|
2018
Q2 | $1.94M | Sell |
22,682
-580
| -2% | -$47.6K | 0.07% | 168 |
|
|
2018
Q1 | $1.8M | Buy |
23,262
+80
| +0.3% | +$6.44K | 0.07% | 174 |
|
|
2017
Q4 | $1.96M | Sell |
23,182
-110
| -0.5% | -$9.36K | 0.07% | 176 |
|
|
2017
Q3 | $1.99M | Buy |
23,292
+200
| +0.9% | +$16.4K | 0.07% | 169 |
|
|
2017
Q2 | $1.9M | Sell |
23,092
-1,000
| -4% | -$81.6K | 0.07% | 171 |
|
|
2017
Q1 | $2.03M | Buy |
24,092
+510
| +2% | +$40.8K | 0.08% | 163 |
|
|
2016
Q4 | $1.73M | Hold |
23,582
| – | – | 0.07% | 169 |
|
|
2016
Q3 | $1.89M | Sell |
23,582
-1,905
| -7% | -$152K | 0.08% | 167 |
|
|
2016
Q2 | $2.01M | Sell |
25,487
-355
| -1% | -$26.7K | 0.08% | 162 |
|
|
2016
Q1 | $1.86M | Buy |
25,842
+1,435
| +6% | +$109K | 0.08% | 167 |
|
|
2015
Q4 | $2.06M | Sell |
24,407
-500
| -2% | -$41.5K | 0.09% | 156 |
|
|
2015
Q3 | $2.08M | Buy |
24,907
+2,000
| +9% | +$169K | 0.09% | 153 |
|
|
2015
Q2 | $1.91M | Hold |
22,907
| – | – | 0.08% | 168 |
|
|
2015
Q1 | $1.66M | Sell |
22,907
-850
| -4% | -$60.5K | 0.07% | 179 |
|
|
2014
Q4 | $1.64M | Sell |
23,757
-500
| -2% | -$33.8K | 0.07% | 176 |
|
|
2014
Q3 | $1.57M | Buy |
24,257
+350
| +1% | +$22.2K | 0.07% | 174 |
|
|
2014
Q2 | $1.49M | Sell |
23,907
-500
| -2% | -$29.8K | 0.07% | 180 |
|
|
2014
Q1 | $1.46M | Hold |
24,407
| – | – | 0.07% | 182 |
|
|
2013
Q4 | $1.25M | Buy |
24,407
+130
| +0.5% | +$6.51K | 0.06% | 185 |
|
|
2013
Q3 | $1.22M | Sell |
24,277
-4,080
| -14% | -$214K | 0.06% | 180 |
|
|
2013
Q2 | $1.39M | Buy |
+28,357
| New | +$1.54M | 0.08% | 167 |
|
Other funds holding LLY
Gofen & Glossberg's LLY Position: Q4 2022 in Review
Gofen & Glossberg increased its Eli Lilly (LLY) stake by 1.6% in Q4 2022, buying an estimated $132K and bringing the position to 24,176 shares worth $8.85M. The position accounts for 0.23% of the portfolio, ranked #101.
Gofen & Glossberg first reported a position in LLY in Q2 2013 and has held it in 39 quarters since. 2,672 funds tracked by Wall St. Rank hold LLY as of Q4 2022.
- Gofen & Glossberg held 24,176 shares of Eli Lilly worth $8.85M as of Q4 2022.
- Gofen & Glossberg bought 372 Eli Lilly shares in Q4 2022, an estimated $132K.
- Eli Lilly made up 0.23% of Gofen & Glossberg's portfolio in Q4 2022, its #101 holding.
- Gofen & Glossberg first reported a position in Eli Lilly in Q2 2013 and has held it in 39 quarters since.
- 2,672 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2022.
Based on Gofen & Glossberg's 13F filing for Q4 2022, filed 13 Jan 2023.